Drugs /

ko 539

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor KO 539 prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.

Clinical Trials

View Clinical Trials for ko 539

Ko 539 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ko 539, 1 is phase 1/phase 2 (1 open).

Acute myeloid leukemia is the most common disease being investigated in ko 539 clinical trials [2].

Drug Details

Synonyms [2]:
menin-mll interaction inhibitor ko 539, menin-mll inhibitor ko-539, menin-mixed lineage leukemia protein-protein interaction inhibitor ko 539, menin-kmt2a inhibitor ko 539, ko539, ko-539
Drug Target(s) [2]:
KMT2A
NCIT ID [1]:
C164227

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.